Very low prevalence of MCR-1/MCR-2 plasmid-mediated colistin resistance in urinary tract Enterobacteriaceae in Switzerland by Liassine, Nadia et al.
International Journal of Infectious Diseases 51 (2016) 4–5Short Communication
Very low prevalence of MCR-1/MCR-2 plasmid-mediated colistin
resistance in urinary tract Enterobacteriaceae in Switzerland
Nadia Liassine a, Laetititia Assouvie b,c, Marie-Christine Descombes d,
Vale´rie De´nervaud Tendon b,c, Nicolas Kieffer b,c, Laurent Poirel b,c, Patrice Nordmann b,c,e,*
aDianalabs SA, Geneva, Switzerland
b Emerging Antibiotic Resistance, Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Fribourg, Switzerland
c INSERM European Unit (LEA Paris), University of Fribourg, Fribourg, Switzerland
d Laboratoire Unilab, Coppet, Switzerland
eUniversity of Lausanne and University Hospital Centre, Lausanne, Switzerland
A R T I C L E I N F O
Article history:
Received 21 July 2016
Received in revised form 9 August 2016
Accepted 11 August 2016
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Polymyxins
MCR
Gram-negative
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idTransferable polymyxin resistance mediated by the mcr-1
plasmid-borne gene has been described recently in Enterobacter-
iaceae, mostly in Escherichia coli, from animals, food, and patients in
China.1 This has raised considerable concern in view of pandrug
resistance in Enterobacteriaceae. MCR-1-producing enterobacterial
pathogens have been reported worldwide. Several cases of
community- and hospital-acquired infection due to mcr-1-positive
E. coli occurring in Switzerland (Geneva and Neuchaˆtel) in
2015 and 2016,2,3 as well as MCR-1-producers in food and river
water,4 have been reported.
Very recently (July 2016), the MCR-2 plasmid-mediated colistin
resistance determinant was identiﬁed in E. coli mainly from pigs in
Belgium.5 MCR-2, which is also a phosphoethanolamine transfer-
ase likely modifying the extremity of the lipopolysaccharide,
shares 80.6% amino acid identity with MCR-1.* Corresponding author.
E-mail address: patrice.nordmann@unifr.ch (P. Nordmann).
http://dx.doi.org/10.1016/j.ijid.2016.08.008
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The aim of this study was to perform a prospective analysis
of the prevalence rate of MCR-1- and MCR-2-producing
Enterobacteriaceae in urine samples obtained from two main
private laboratories in Switzerland during the period February
to March 2016. The study was focused on urinary tract
infections (UTIs) since (1) they still represent the main source
of infection for humans, and (2) E. coli from community-
acquired infections is at the interplay between the environment
and hospitals, playing a potential role as an exchange platform
for mcr-like genes. Strains were collected from the same region
of Switzerland where mcr-1-positive E. coli was identiﬁed
previously.
A total of 2049 non-duplicate enterobacterial isolates were
screened. These included E. coli (n = 1704), Klebsiella pneumoniae (n
= 151), Proteus mirabilis (n = 73), Citrobacter sp (n = 32), Klebsiella
oxytoca (n = 22), Enterobacter cloacae (n = 18), Morganella morganii
(n = 13), Enterobacter aerogenes (n = 15), Proteus vulgaris (n = 7),
Serratia sp (n = 7), Providencia rettgeri (n = 3), Salmonella group D (n
= 2), Hafnia alvei (n = 1), and Kluyvera ascorbata (n = 1). The
predominance of E. coli isolates in this collection mirrors theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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ﬁrst screened using the recently developed rapid polymyxin NP
test, which is a rapid technique for the detection of colistin
resistance.6 Strains were then screened for the mcr-1 and mcr-2
genes using regular PCR techniques (mcr-2 full Fw 50-ATG ACA
TCA CAT CAC TCT TGG-30 and mcr-2 full Rv 50-TTA CTG GAT AAA
TGC CGC GC- 30; cycling conditions of 34 cycles of 95 8C  1 min,
52 8C  30 s, 72 8C  1 min, followed by 1 cycle of 72 8C  5 min)
and the real-time PCR technique for the mcr-1 gene.7,8
According to the results of the rapid polymyxin NP test, six
isolates were resistant to colistin (prevalence rate, 0.29%): two E.
coli, two K. pneumoniae, one H. alvei, and one Salmonella isolate.
Determination of the minimum inhibitory concentration (MIC)
performed by broth microdilution conﬁrmed that these six strains
were resistant to colistin (MIC > 2 mg/l), with MIC values of
colistin ranging from 4 to >128 mg/l.
PCRs targeting the mcr-like genes performed on the colistin-
resistant isolates remained negative. However, when testing
colistin-susceptible isolates, a single E. coli strain (C1624) was
positive for the mcr-1 gene. The MIC value of colistin for this isolate
was 0.125 mg/l (European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) breakpoint tables for the interpretation of
MICs and zone diameters, version 2.0, 2014). Southern hybridiza-
tion using an mcr-1 fragment of approximately 600 bp as a probe
identiﬁed this gene located on a plasmid of approximately 35 kb.
This plasmid was not transferable using liquid or solid mating
techniques.7 Multilocus sequence typing of E. coli C1624 showed
that it belonged to sequence type ST428 (http://mlst.warwick.-
ac.uk/mlst/dbs/Ecoli/).7 This sequence type has been identiﬁed in
infections of broiler breeders, further suggesting the animal origin
of the MCR-like-producers.9
The overall prevalence rate of MCR-producing enterobacterial
strains from human UTIs in this region of Western Europe remains
very low (0.05%). This prevalence rate is somewhat similar to that
observed recently in a large study of enterobacterial strains
isolated worldwide from 2014 to 2015 (<0.1%).10 It might be the
consequence of a lack of selection of MCR-producing bacteria due
to the lack of colistin use for the treatment of community-acquired
infections. This low prevalence rate despite the use of colistin to
treat infected animals in Switzerland suggests that a high transfer
of mcr-like genes from animal (or environmental) strains to human
strains has not already occurred. This further indicates the
possibility of preventing the wide dissemination of mcr-like-
producing bacteria in human medicine. However, the identiﬁca-
tion of a colistin-susceptible/mcr-1-positive isolate in the present
study indicates that the silent spread of this gene might happen. An
important step in preventing the spread of MCR-like-producerswould be to implement large and regular screening of animal
isolates.
Finally, this study represents the ﬁrst screening of human
isolates for the mcr-2 gene, a gene that has only been found in a few
animal isolates. It is believed that this screening of MCR-producers
characterizes the most recently available collection of strains . It
may therefore represent the true prevalence rate of MCR-
producers in this region of the world.
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